The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The 60th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from 1–4 December 2018. On Sunday 2 December 2018, an oral abstract session was held entitled: Myeloma: Therapy, excluding Transplantation: Novel Targeted Combinations in Myeloma, which focused on updates of clinical trials using novel combination regimens for patients with multiple myeloma (MM).
Meletios A. Dimopoulos from the School of Medicine, Athens, Greece, presented results from the phase III Tourmaline-MM3 clinical trial.1 This randomized, placebo-controlled study examined the safety and efficacy of maintenance therapy using the proteasome inhibitor (PI) ixazomib.
The rationale behind this study relies on the fact that lenalidomide, the approved immunomodulatory (IMiD) drug for maintenance therapy, results in treatment-emergent adverse events (AEs) in 29% of the treated patients. It is possible that a PI, which has a different mode of action to that of lenalidomide, may be better tolerated and may provide a more effective maintenance alternative, at least to a subgroup of patients.
The primary endpoint was progression-free survival (PFS) and the key secondary point, overall survival (OS). The results presented at ASH 2018 were recently published at Lancet.2
Results are presented as ixazomib maintenance versus (vs) placebo.
The TOURMALINE-MM3 trial met its primary endpoint. Ixazomib maintenance was well tolerated and significantly improved PFS for 24 months compared to placebo.